Evidence map›Paper›PMID 42273802›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Lars L Raket, Ming Lu, Cynthia D Evans, Jennifer A Zimmer, JonDavid Sparks, Emily C Collins, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Stéphane Epelbaum and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04437511 (Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04437511 phase3active not recruitingnot on this map

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

TypeinterventionalSponsorEli Lilly and CompanyRan2020 to 2028Enrolled1,736ConditionsAlzheimer DiseaseArmsDonanemab, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The value of timely treatment with anti-amyloid therapy for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lars L RaketEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0001-7099-2314
Ming LuEli Lilly and Company, Indianapolis, Indiana, USA.
Cynthia D EvansEli Lilly and Company, Indianapolis, Indiana, USA.
Jennifer A ZimmerEli Lilly and Company, Indianapolis, Indiana, USA.
JonDavid SparksEli Lilly and Company, Indianapolis, Indiana, USA.
Emily C CollinsEli Lilly and Company, Indianapolis, Indiana, USA.
Sergey ShcherbininEli Lilly and Company, Indianapolis, Indiana, USA.
Hong WangEli Lilly and Company, Indianapolis, Indiana, USA.
Emel Serap Monkul NeryEli Lilly and Company, Indianapolis, Indiana, USA.
Stéphane EpelbaumEli Lilly and Company, Indianapolis, Indiana, USA.
Grazia Dell'AgnelloEli Lilly and Company, Indianapolis, Indiana, USA.
Dawn A BrooksEli Lilly and Company, Indianapolis, Indiana, USA.
John R SimsEli Lilly and Company, Indianapolis, Indiana, USA.
Mark A MintunEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

introductionClinical trials indicate that disease-modifying therapies can slow clinical decline in Alzheimer's disease (AD), with earlier initiation associated with greater slowing.

methodsIn the TRAILBLAZER-ALZ 2 trial, the treatment effect of donanemab on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score was assessed across disease stages defined by baseline tau PET, plasma P-tau217 levels, or predicted disease progression.

resultsDonanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels. Participants with lower baseline tau PET and P-tau217 showed greater slowing with donanemab versus placebo. Modeling CDR-SB scores indicated that earlier treatment (at the 25 DISCUSSION: Donanemab benefited participants with early symptomatic AD across clinical and pathological severities, with the greatest slowing in those treated earlier. CLINICALTRIALS: gov Identifier: NCT04437511.

Indexed as

Alzheimer Diseasetau ProteinsAgedAntibodies, Monoclonal, HumanizedDisease ProgressionDouble-Blind MethodFemaleHumansMalePositron-Emission TomographySeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, Humanizeddonanemabtau ProteinsAlzheimer's diseaseamyloid‐targeting therapydisease progression modelingneurodegenerationP‐tau217tau PET

Identifiers

PMID42273802
PMCPMC13254682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.